zw251
·Code: ZW251
zw251: 1 clinical trial tracked.
zw251 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about zw251, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
A First-In-Human, Phase 1, Open-Label, Multicenter Study of ZW251, a Novel Glypican-3 Targeting Antibody-Drug Conjugate, in Participants With Advanced Solid Tumors, Including Hepatocellular Carcinoma
Primary endpoint: Incidence of dose-limiting toxicities (DLTs; Part 1)
Interventionalopen140 targetStarted 2025-10Completion 2028-0525 sites · Ireland, Japan, Portugal, Spain…Zymeworks BC Inc.